Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 186

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 186
---
000 to an annual rate of $280,000, effective as of October 16, 2024. Outstanding Equity Awards at 2024 Fiscal Year-End The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of December 31, 2024.

| ​               
 Name            | ​ 
 ​ | Option awards 
 Vesting       
 Commencement  
 date          | ​ |   Number of 
  securities 
  underlying 
 unexercised 
 options (#) 
 exercisable | ​ |     Number of 
    securities 
    underlying 
   unexercised 
   options (#) 
 unexercisable | ​ | Option    
 Exercise  
 Price ($) |       | ​ | Option     
 Expiration 
 Date       | ​ 
 ​ |
|:----------------|:--|:--------------|:--|------------:|:--|--------------:|:--|:----------|------:|:--|:-----------|:--|
| Fady Boctor     | ​ | 2/19/2021     | ​ |      21,567 | ​ |             — | ​ | $         | 37.40 | ​ | 2/19/2031  | ​ |
|                 | ​ | 12/21/2023    | ​ |      54,533 | ​ |        54,533 | ​ | $         |  1.41 | ​ | 12/21/2033 | ​ |
| Mitchell Arnold | ​ | 5/11/2021     | ​ |       5,000 | ​ |             — | ​ | $         | 32.10 | ​ | 5/11/2031  | ​ |
|                 | ​ | 12/21/2023    | ​ |      20,000 | ​ |             — | ​ | $         |  1.41 | ​ | 12/21/2033 | ​ |

Accounting and Tax Considerations Section 162(m) of the Code places a limit of $1,000,000 on the amount of compensation that a public company may deduct as a business expense in any year with respect to such company’s chief executive officer, certain other named executive officers, and all “covered employees” as defined by Section 162(m). The Company’s Compensation Committee intends to maximize deductibility of compensation under Section 162(m) to the extent practicable while maintaining a competitive, performance-based compensation